Cargando…

Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout

BACKGROUND AND OBJECTIVES: Topiroxostat—a novel selective xanthine oxidoreductase inhibitor—has been reported to reduce serum urate levels. The purpose of this study was to assess the efficacy and safety of long-term topiroxostat administration in Japanese hyperuricemic patients with or without gout...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Ishikawa, Tomohiko, Ogawa, Yoshimi, Sakamoto, Ryusuke, Ohashi, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267543/
https://www.ncbi.nlm.nih.gov/pubmed/30219951
http://dx.doi.org/10.1007/s40261-018-0699-0
_version_ 1783376098919186432
author Hosoya, Tatsuo
Ishikawa, Tomohiko
Ogawa, Yoshimi
Sakamoto, Ryusuke
Ohashi, Tetsuo
author_facet Hosoya, Tatsuo
Ishikawa, Tomohiko
Ogawa, Yoshimi
Sakamoto, Ryusuke
Ohashi, Tetsuo
author_sort Hosoya, Tatsuo
collection PubMed
description BACKGROUND AND OBJECTIVES: Topiroxostat—a novel selective xanthine oxidoreductase inhibitor—has been reported to reduce serum urate levels. The purpose of this study was to assess the efficacy and safety of long-term topiroxostat administration in Japanese hyperuricemic patients with or without gout. METHODS: This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or  without gout. The initial topiroxostat dosage was 40–80 mg/day, and the maintenance dosage was 120 mg/day, which was increased to 240 mg/day at 40 mg increments if the serum urate level exceeded 6.0 mg/dL. RESULTS: Serum urate level, which was the primary endpoint, decreased stably over time and showed significant reduction on the final visit (38.44% ± 13.34%) compared with that at the baseline. Both urinary albumin/creatinine ratio and mean blood pressure significantly improved. The overall incidence rate of adverse drug reactions to topiroxostat was 67.8%; on the final visit, the rate of adverse drug reactions was 66.7% with 120 mg/day, 72.2% with 160 mg/day, 53.8% with ≥ 200 mg/day, and 100% with the other dosages. On the final visit, the incidence of gouty arthritis, for which a causal relationship with topiroxostat could not be ruled out, was 4.1% overall, 4.8% with 120 mg/day, 0% with 160 mg/day, and 7.7% with ≥ 200 mg/day. CONCLUSIONS: We verified the efficacy and safety of 58-week oral topiroxostat administration at stepwise increments to up to 240 mg/day. STUDY REGISTRATION: JAPIC CTI-101068.
format Online
Article
Text
id pubmed-6267543
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-62675432018-12-11 Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout Hosoya, Tatsuo Ishikawa, Tomohiko Ogawa, Yoshimi Sakamoto, Ryusuke Ohashi, Tetsuo Clin Drug Investig Original Research Article BACKGROUND AND OBJECTIVES: Topiroxostat—a novel selective xanthine oxidoreductase inhibitor—has been reported to reduce serum urate levels. The purpose of this study was to assess the efficacy and safety of long-term topiroxostat administration in Japanese hyperuricemic patients with or without gout. METHODS: This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or  without gout. The initial topiroxostat dosage was 40–80 mg/day, and the maintenance dosage was 120 mg/day, which was increased to 240 mg/day at 40 mg increments if the serum urate level exceeded 6.0 mg/dL. RESULTS: Serum urate level, which was the primary endpoint, decreased stably over time and showed significant reduction on the final visit (38.44% ± 13.34%) compared with that at the baseline. Both urinary albumin/creatinine ratio and mean blood pressure significantly improved. The overall incidence rate of adverse drug reactions to topiroxostat was 67.8%; on the final visit, the rate of adverse drug reactions was 66.7% with 120 mg/day, 72.2% with 160 mg/day, 53.8% with ≥ 200 mg/day, and 100% with the other dosages. On the final visit, the incidence of gouty arthritis, for which a causal relationship with topiroxostat could not be ruled out, was 4.1% overall, 4.8% with 120 mg/day, 0% with 160 mg/day, and 7.7% with ≥ 200 mg/day. CONCLUSIONS: We verified the efficacy and safety of 58-week oral topiroxostat administration at stepwise increments to up to 240 mg/day. STUDY REGISTRATION: JAPIC CTI-101068. Springer International Publishing 2018-09-15 2018 /pmc/articles/PMC6267543/ /pubmed/30219951 http://dx.doi.org/10.1007/s40261-018-0699-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Hosoya, Tatsuo
Ishikawa, Tomohiko
Ogawa, Yoshimi
Sakamoto, Ryusuke
Ohashi, Tetsuo
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title_full Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title_fullStr Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title_full_unstemmed Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title_short Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
title_sort multicenter, open-label study of long-term topiroxostat (fyx-051) administration in japanese hyperuricemic patients with or without gout
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267543/
https://www.ncbi.nlm.nih.gov/pubmed/30219951
http://dx.doi.org/10.1007/s40261-018-0699-0
work_keys_str_mv AT hosoyatatsuo multicenteropenlabelstudyoflongtermtopiroxostatfyx051administrationinjapanesehyperuricemicpatientswithorwithoutgout
AT ishikawatomohiko multicenteropenlabelstudyoflongtermtopiroxostatfyx051administrationinjapanesehyperuricemicpatientswithorwithoutgout
AT ogawayoshimi multicenteropenlabelstudyoflongtermtopiroxostatfyx051administrationinjapanesehyperuricemicpatientswithorwithoutgout
AT sakamotoryusuke multicenteropenlabelstudyoflongtermtopiroxostatfyx051administrationinjapanesehyperuricemicpatientswithorwithoutgout
AT ohashitetsuo multicenteropenlabelstudyoflongtermtopiroxostatfyx051administrationinjapanesehyperuricemicpatientswithorwithoutgout